WEST CHESTER, Pa. - Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), a dermatology therapeutics company with a current market capitalization of $61.25 million, has announced an operational update highlighting an increase in dispensed units of its lead product, YCANTH, for the treatment of molluscum contagiosum. According to InvestingPro data, while the stock has seen significant pressure, trading at $0.68 and down nearly 88% over the past year, analysis suggests the company may be undervalued at current levels. The fourth quarter of 2024 saw a rise in dispensed applicator units surpassing those of the previous quarter, alongside significant cost reductions in sales and operational infrastructure.
The company has also observed a considerable reduction in distributor inventory levels for YCANTH. In response to growing demand, Verrica is expanding distribution capabilities, including making YCANTH available through local independent pharmacies. Despite impressive revenue growth of 187.45% in the last twelve months, InvestingPro analysis reveals the company is quickly burning through cash, with negative free cash flow of $59.62 million. A new single applicator configuration is expected to be released in the first quarter of 2025, which aims to reduce acquisition costs for healthcare providers and increase patient access by offering more purchasing options to buying groups and government entities.
President and CEO of Verrica, Jayson Rieger, PhD MBA, stated that these developments are part of a focused commercial strategy for YCANTH, which has been supported by recent financing efforts to strengthen the company's balance sheet and improve operational efficiencies.
Additionally, Verrica is advancing its product pipeline, including candidates for the treatment of common warts and basal cell carcinoma. The company's partnership with Torii Pharmaceutical (TADAWUL:2070) continues to progress YCANTH for the treatment of common warts in Japan, and preliminary data from a Phase 2 study suggests potential for VP-315 as a new treatment approach for basal cell carcinoma.
YCANTH (VP-102) is the first FDA-approved treatment for molluscum contagiosum in patients two years of age and older. The product's approval was based on positive results from two Phase 3 clinical trials. YCANTH is covered by insurance for approximately 228 million lives and is available for $25 per treatment, with additional financial assistance for those in need.
This update is based on a press release statement from Verrica Pharmaceuticals Inc. and is intended to provide an overview of the company's recent business developments and future expectations. For investors seeking deeper insights, InvestingPro offers a comprehensive research report on Verrica Pharmaceuticals, including detailed financial analysis, 12 additional ProTips, and expert insights on the company's growth prospects and challenges.
In other recent news, Verrica Pharmaceuticals has seen significant operational changes. The company announced the appointment of David Zawitz as its new Chief Operating Officer, a strategic move following a thorough selection process by the Board of Directors. This move comes amid financial challenges with negative EBITDA of -$73.4 million in the last twelve months, as reported by InvestingPro.
Verrica's partner, Torii Pharmaceutical Co. Ltd., has submitted a New Drug Application in Japan for TO-208, marking a significant step in making the first therapeutic for Molluscum Contagiosum available in Japan. This development is accompanied by a reported impressive revenue growth of 187% in the last twelve months.
In terms of analyst outlooks, TD Cowen revised its price target for Verrica to $10.00 from $15.00, maintaining a Buy rating. Needham downgraded the company's stock from Buy to Hold, while RBC Capital maintained an Outperform rating, albeit reducing the stock's price target to $13 from $14.
Lastly, Verrica reported positive preliminary open-label phase II data from VP-315 for the treatment of basal cell carcinoma, with complete clearance in 51% of treated lesions. These are the recent developments for Verrica Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.